We will find out soon what caused today's move, imo. Only catalyst in Q3 is the FDA meeting on phase 2 Ovarian. I don't think that was the cause of today's move because the data has been published. Perhaps the phase 2 went well and VB-111 received fast track designation for ovarian?
The company is also actively looking for partners for its NASH products so that can happen at any time.